| 病例报告 |
|
|
|
|
| 托珠单抗联合芦可替尼治疗造血干细胞移植后激素耐药的移植物抗宿主病患儿六例 |
陈洁,陆婧媛,洪秀理,鹿全意( ) |
| 厦门大学附属中山医院血液科，福建 厦门 361000 |
|
| Tocilizumab combined with ruxolitinib in the treatment of children with steroid resistant graft versus host disease after hematopoietic stem cell transplantation: report of 6 cases |
| CHEN Jie,LU Jingyuan,HONG Xiuli,LU Quanyi() |
| Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen 361000, Fujian Province, China |
引用本文:
陈洁,陆婧媛,洪秀理,鹿全意. 托珠单抗联合芦可替尼治疗造血干细胞移植后激素耐药的移植物抗宿主病患儿六例[J]. 浙江大学学报（医学版）, 2022, 51(4): 470-473.
CHEN Jie,LU Jingyuan,HONG Xiuli,LU Quanyi. Tocilizumab combined with ruxolitinib in the treatment of children with steroid resistant graft versus host disease after hematopoietic stem cell transplantation: report of 6 cases. J Zhejiang Univ (Med Sci), 2022, 51(4): 470-473.
链接本文:
https://www.zjujournals.com/med/CN/10.3724/zdxbyxb-2022-0245
或
https://www.zjujournals.com/med/CN/Y2022/V51/I4/470
|
| 1 |
D’SOUZA A , LEE S , ZHU X , et al.Current use and trends in hematopoietic cell transplantation in the united states[J]Biol Blood Marrow Transplant, 2017, 23( 9): 1417-1421.
doi: 10.1016/j.bbmt.2017.05.035
|
| 2 |
MACMILLAN M L , WEISDORF D J , WAGNER J E , et al.Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems[J]Biol Blood Marrow Transplant, 2002, 8( 7): 387-394.
doi: 10.1053/bbmt.2002.v8.pm12171485
|
| 3 |
KIM J G , SOHN S K , KIM D H , et al.Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant[J]Eur J Haematol, 2004, 73( 1): 56-61.
doi: 10.1111/j.1600-0609.2004.00247.x
|
| 4 |
BOLAÑOS-MEADE J , JACOBSOHN D A , MARGOLIS J , et al.Pentostatin in steroid-refractory acute graft-versus-host disease[J]J Clin Oncol, 2005, 23( 12): 2661-2668.
doi: 10.1200/JCO.2005.06.130
|
| 5 |
WESTIN J R , SALIBA R M , DE LIMA M , et al.Steroid-refractory acute GVHD: predictors and outcomes[J]Adv Hematol, 2011, 601953.
doi: 10.1155/2011/601953
|
| 6 |
BENITO A I , FURLONG T , MARTIN P J , et al.Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease[J]Transplantation, 2001, 72( 12): 1924-1929.
doi: 10.1097/00007890-200112270-00010
|
| 7 |
HODA D , PIDALA J , SALGADO-VILA N , et al.Sirolimus for treatment of steroid-refractory acute graft-versus-host disease[J]Bone Marrow TransPlant, 2010, 45( 8): 1347-1351.
doi: 10.1038/bmt.2009.343
|
| 8 |
TANAKA T , NARAZAKI M , KISHIMOTO T . Therapeutic targeting of the interleukin-6 receptor[J]Annu Rev Pharmacol Toxicol, 2012, 52( 1): 199-219.
doi: 10.1146/annurev-pharmtox-010611-134715
|
| 9 |
CHEN X , DAS R , KOMOROWSKI R , et al.Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease[J]Blood, 2009, 114( 4): 891-900.
doi: 10.1182/blood-2009-01-197178
|
| 10 |
TAWARA I , KOYAMA M , LIU C , et al.Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation[J]Clin Cancer Res, 2011, 17( 1): 77-88.
doi: 10.1158/1078-0432.CCR-10-1198
|
| 11 |
DROBYSKI W R , PASQUINI M , KOVATOVIC K , et al.Tocilizumab for the treatment of steroid refractory graft-versus-host disease[J]Biol Blood Marrow Transplant, 2011, 17( 12): 1862-1868.
doi: 10.1016/j.bbmt.2011.07.001
|
| 12 |
RODDY J V F , HAVERKOS B M , MCBRIDE A , et al.Tocilizumab for steroid refractory acute graft-versus-host disease[J]Leuk Lymphoma, 2016, 57( 1): 81-85.
doi: 10.3109/10428194.2015.1045896
|
| 13 |
洪秀理, 陆婧媛, 陈亚枚, 等. 减低剂量预处理的造血干细胞移植治疗儿童β珠蛋白生成障碍性贫血[J]. 中华器官移植杂志, 2018, 39(2): 92-95
HONG Xiuli, LU Jingyuan, CHEN Yamei, et al. Allogeneic hematopoietic stem cell transplantation for β-thalassemia major patients using a reduced-intensity conditioning regimen[J]. Chinese Journal of Organ Transplantation, 2018, 39(2): 92-95. (in Chinese)
|
| 14 |
王晓宁, 张 莹, 刘欣慰, 等. 异基因造血干细胞移植后激素耐药胃肠道急性移植物抗宿主病的临床分析[J/CD]. 中华细胞与干细胞杂志(电子版), 2020, 10(6): 336-340
WANG Xiaoning, ZHANG Ying, LIU Xinwei, et al. Clinical analysis of steroid-resistant acute gastrointestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation[J/CD]. Chinese Journal of Cell and Stem Cell (Electronic Edition), 2020, 10(6): 336-340. (in Chinese)
|
| 15 |
YUCEBAY F , MATTHEWS C , PUTO M , et al.Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience[J]Leuk Lymphoma, 2019, 60( 9): 2223-2229.
doi: 10.1080/10428194.2019.1573996
|
| 16 |
HILL L Q , ALOUSI A , KEBRIAEI P , et al.New and emerging therapies for acute and chronic graft versus host disease[J]Therapeutic Adv Hematol, 2018, 9( 1): 21-46.
doi: 10.1177/2040620717741860
|
| 17 |
KENNEDY G A , VARELIAS A , VUCKOVIC S , et al.Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial[J]Lancet Oncol, 2014, 15( 13): 1451-1459.
doi: 10.1016/S1470-2045(14)71017-4
|
| 18 |
LOUISE L, BENEDICTE N, JEAN-HUGUES D, et al. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: a retrospective multicenter study of the pediatric group of SFGM-TC[J/OL]. Pediatr Blood Cancer, 2020, 67(9): e28233
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
